Wells Fargo analyst Mike Mayo maintains Goldman Sachs Group (NYSE:GS) with a Overweight and lowers the price target from $420 to $380.
FDA Rejects Ascendis Pharma’s TransCon PTH For Hypoparathyroidism
The FDA issued a complete response letter (CRL) for Ascendis Pharma A/S's